Short-term orlistat therapy improves fatty infiltration indices and liver fibrosis scores in patients with non-alcoholic fatty liver disease and metabolic syndrome |
| |
| Authors: | Vian Ahmed Wasta Esmail Mohammed Omer Mohammed Marwan S.M. Al-Nimer |
| |
| Affiliation: | 1. Department of Clinical Pharmacy, College of Pharmacy, University of Sulaimani, Sulaimani, Iraq;2. Department of Medicine, Department of Pharmacology, College of Medicine, University of Sulaimani, Sulaimani, Iraq;3. Department of Pharmacology and Toxicology, College of Pharmacy, Hawler Medical University, Erbil, Iraq;1. Department of Gastroenterology, The Second Hospital, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China;2. Endoscopy Center, Affiliated Tumor Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, PR China;1. Department of Tropical Medicine, Ain Shams University, Cairo, Egypt;2. Department of Clinical and Chemical Pathology, Kasr Al-Ainy School of Medicine, Cairo University, Manial Street, Cairo 11562, Egypt;1. Department of Gastroenterology, Gulhane Faculty of Medicine, University of Health Sciences, Ankara, Turkey;2. Department of Psychiatry, Gulhane Faculty of Medicine, University of Health Sciences, Ankara, Turkey;3. Department of Psychiatry, Ataturk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Turkey;4. Department of Statistics, Faculty of Science, Gazi University, Ankara, Turkey;1. Liver and Digestive Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran;2. Cellular and Molecular Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran;3. Cancer and Immunology Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran;1. Division of Gastroenterology, American University of Beirut Medical Center, P.O. Box 11-0236/16-B, Beirut, Lebanon;2. Department of Pathology & Laboratory Medicine, American University of Beirut Medical Center, PO Box 11-0236, Riad El Solh 11072020, Beirut, Lebanon |
| |
| Abstract: | Background and study aimsPatients with non-alcoholic fatty liver disease (NAFLD) exhibit features of metabolic syndrome, including a high body mass index, central obesity, high blood pressure, and abnormal lipid profile values. Orlistat, an intestinal lipase enzyme inhibitor, improves insulin resistance. We aimed to investigate the effects of short-term therapy with orlistat on the components of metabolic syndrome associated with NAFLD and explore its effect on liver fibrosis scores.Patients and methodsAn open-label placebo-controlled clinical study using orlistat for 12 weeks was carried out on 50 patients with NAFLD. They were divided into a placebo group (Group I) and an orlistat treatment group (120 mg per day, Group II). The diagnosis of NAFLD was made by ultrasonography and laboratory investigations. Anthropometric and blood pressure measurements and hepatic liver enzymes, fasting lipids, and blood glucose levels were determined before and after treatment. Lipid indices including cholesterol (Chol-I), triglyceride (TG-I), triglyceride-glucose (TYG-I), and the scores for lipid fibrosis using the NAFLD fibrosis score (NFS) and Fibrosis-4 score (Fib-4) were also determined.ResultsOrlistat significantly improved the anthropometric and metabolic indices (TG-I, TYG-I) and liver enzymes. Orlistat demonstrated a favorable impact on the NAS and Fib-4 scores for liver fibrosis.ConclusionOrlistat improves the components of metabolic syndrome, leading to the improvement of insulin resistance and thereby improves fatty infiltration of the liver. To a lesser extent, orlistat improved the liver fibrosis scores. |
| |
| Keywords: | Non-alcoholic fatty liver disease Metabolic syndrome Lipid indices Liver fibrosis scores |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
